Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1989 2
1995 2
1996 1
2001 2
2002 2
2003 2
2005 1
2006 1
2007 1
2008 1
2010 3
2011 1
2013 1
2014 1
2017 1
2018 1
2019 2
2020 1
2021 3
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ. Provan D, et al. Among authors: gernsheimer t. Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812. Blood Adv. 2019. PMID: 31770441 Free PMC article.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Kuter DJ, et al. Among authors: gernsheimer t. N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297. N Engl J Med. 2022. PMID: 35417637 Clinical Trial.
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A. Al-Samkari H, et al. Among authors: gernsheimer t. Br J Haematol. 2022 May;197(3):359-366. doi: 10.1111/bjh.18081. Epub 2022 Feb 18. Br J Haematol. 2022. PMID: 35179784 Free PMC article.

In all patients, the median platelet count on eltrombopag or romiplostim was 45 10(9) /l vs 114 10(9) /l on avatrombopag (p < 0.0001); in patients switched for ineffectiveness of romiplostim/eltrombopag, it was 28 10(9) /l on romiplostim/eltrombopag vs 88 10(9) /l on av

In all patients, the median platelet count on eltrombopag or romiplostim was 45 10(9) /l vs 114 10(9) /l on avatrombopag (p < 0.00

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial.
Gernsheimer TB, Brown SP, Triulzi DJ, Key NS, El Kassar N, Herren H, Poston JN, Boyiadzis M, Reeves BN, Selukar S, Pagano MB, Emerson S, May S. Gernsheimer TB, et al. Blood. 2022 Sep 15;140(11):1254-1262. doi: 10.1182/blood.2022016308. Blood. 2022. PMID: 35667085 Free PMC article. Clinical Trial.
World Health Organization (WHO) grade 2 bleeding was observed in the 30 days following activation in 50.3% (73/145) and 54.2% (78/144) of patients in the TXA and placebo groups, with an adjusted odds ratio of 0.83 (95% confidence interval [CI], 0.50-1.34; P = .44). There w …
World Health Organization (WHO) grade 2 bleeding was observed in the 30 days following activation in 50.3% (73/145) and 54.2% (78/144) of pa …
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
Kuter DJ, Mayer J, Efraim M, Bogdanov LH, Baker R, Kaplan Z, Garg M, Trněný M, Choi PY, Jansen AJG, McDonald V, Bird R, Gumulec J, Kostal M, Gernsheimer T, Ghanima W, Daak A, Cooper N. Kuter DJ, et al. Among authors: gernsheimer t. Blood Adv. 2024 Apr 9;8(7):1715-1724. doi: 10.1182/bloodadvances.2023012044. Blood Adv. 2024. PMID: 38386978 Free PMC article. Clinical Trial.
Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.
Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, Semple JW, Arnold DM, Godeau B, Lambert MP, Bussel JB. Lee EJ, et al. Among authors: gernsheimer t. Am J Hematol. 2021 May 1;96(5):534-537. doi: 10.1002/ajh.26132. Epub 2021 Mar 9. Am J Hematol. 2021. PMID: 33606296 Free PMC article. No abstract available.
Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference.
Spinella PC, El Kassar N, Cap AP, Kindzelski AL, Almond CS, Barkun A, Gernsheimer TB, Goldstein JN, Holcomb JB, Iorio A, Jensen DM, Key NS, Levy JH, Mayer SA, Moore EE, Stanworth SJ, Lewis RJ, Steiner ME; Hemostasis Trials Outcomes Working Group. Spinella PC, et al. Among authors: gernsheimer tb. J Trauma Acute Care Surg. 2021 Aug 1;91(2S Suppl 2):S19-S25. doi: 10.1097/TA.0000000000003300. J Trauma Acute Care Surg. 2021. PMID: 34039915 Free PMC article.
The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview.
Busch MP, Collier A, Gernsheimer T, Carrington JD, Flanigan TP, Kashkari M, Kennedy M, Kumar PN, Lane TA, Mellors JW, Mohandas K, Pollard RB, Viele M, Yomtovian R, Holland PV, McCurdy PR. Busch MP, et al. Among authors: gernsheimer t. Transfusion. 1996 Oct;36(10):854-9. doi: 10.1046/j.1537-2995.1996.361097017169.x. Transfusion. 1996. PMID: 8863770 Review. No abstract available.
Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients.
Chan EY, Larson AM, Gernsheimer TB, Kowdley KV, Carithers RL Jr, Reyes JD, Perkins JD. Chan EY, et al. Among authors: gernsheimer tb. Liver Transpl. 2007 Apr;13(4):516-22. doi: 10.1002/lt.21082. Liver Transpl. 2007. PMID: 17394149 Free article. Review.
Percentages of liver disease etiologies among the patients who developed GVHD were as follows: 16% (1/6) autoimmune hepatitis (AIH) (P = 0.003), 5.6% (3/54) alcoholic liver disease (ALD) (P = 0.057), and 7.1% (3/42) hepatocellular carcinoma (HCC) (P = 0.026). …
Percentages of liver disease etiologies among the patients who developed GVHD were as follows: 16% (1/6) autoimmune hepatitis (AIH) (P
Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia.
Slichter SJ, Dumont LJ, Cancelas JA, Jones M, Gernsheimer TB, Szczepiorkowski ZM, Dunbar NM, Prakash G, Medlin S, Rugg N, Kinne B, Macdonald VW, Housler G, Valiyaveettil M, Hmel P, Ransom JH. Slichter SJ, et al. Among authors: gernsheimer tb. Transfusion. 2018 Sep;58(9):2129-2138. doi: 10.1111/trf.14780. Transfusion. 2018. PMID: 30204953 Clinical Trial.
34 results